Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary

Journal of Surgical Oncology

Volumn 94, Issue 2, 2006, Pages 138-143

  Mizuno, Mika ^a   Kikkawa, Fumitaka ^b   Shibata, Kiyosumi ^b   Kajiyama, Hiroaki ^b   Ino, Kazuhiko ^b   Kawai, Michiyasu ^c   Nagasaka, Tetsuro ^d   Nomura, Seiji ^b  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Residual tumor; Serous cystadenocarcinoma; Stage

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES TUMOR; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL RATE; ADENOCARCINOMA; COMPARATIVE STUDY; MORTALITY; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA, CLEAR CELL; CYSTADENOCARCINOMA, SEROUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33747088935     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20251     Document Type: Article

References (18)

1. Kikkawa F, Matsuzawa K, Arii Y, et al.: Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer. Gynecol Obstet Invest 2000;50:269-274.
2. Brun JL, Feyler A, Chene G, et al.: Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:21-27.
3. Bristow RE, Montz FJ, Lagasse LD, et al.: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278-287.
4. Markman M, Liu PY, Wilczynski S, et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21:2460-2465.
5. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
6. Sugiyama T, Kamura T, Kigawa J, et al.: Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589.
7. Kennedy AW, Biscotti CV, Hart WR, et al.: Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-349.
8. Kennedy AW, Markman M, Biscotti CV, et al.: Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol 1999;74:108-114.
9. O'Brien ME, Schofield JB, Tan S, et al.: Clear cell epithelial ovarian cancer (mesonephroid): Bad prognosis only in early stages. Gynecol Oncol 1993;49:250-254.
10. Jenison EL, Montag AG, Griffiths CT, et al.: Clear cell adenocarcinoma of the ovary: A clinical analysts and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
11. Vergote I, De Brabanter J, Fyles A, et al.: Prognostic importance of degree of differentiation and cyst rupture in stage 1 invasive epithelial ovarian carcinoma. Lancet 2001;357:176-182.
12. Mizuno M, Kikkawa F, Shibata K, et al.: Long-term prognosis of stage 1 ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 2003;65:29-36.
13. Parker D, Bradley C, Bogle SM, et al.: Serum albumin and CA125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:888-893.
14. Fisken J, Leonard RC, Stewart M, et al.: The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma. Br J Cancer 1993;68:140-145.
15. Omura GA, Brady MF, Homesley HD, et al.: Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J Clin Oncol 1991; 9:1138-1150.
16. Tokuhashi Y, Kikkawa F, Tamakoshi K, et al.: A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer. Oncology 1997;54:281-286.
17. Hoskins WJ, Bundy BN, Thigpen JT, et al.: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-166.
18. Hoskins WJ, McGuire WP, Brady MF, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-979; discussion 979-980.